Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe on...

Full description

Bibliographic Details
Main Authors: Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut Smerud, Stig Palm
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Medicine
Subjects:
targeted alpha therapy
alpha particle
astatine-211
radionuclide
human
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1076210/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1076210/full

Similar Items